Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

834.04
+7.400.90%
Post-market: 834.040.00000.00%19:58 EDT
Volume:786.92K
Turnover:656.91M
Market Cap:85.87B
PE:20.63
High:847.00
Open:835.74
Low:826.64
Close:826.64
52wk High:847.00
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:1.27
T/O Rate:0.80%
Dividend:3.64
Dividend Rate:0.44%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.71
PE(LYR):20.11

Loading ...

Regeneron Pharmaceuticals (REGN) Wins Pasatru Approval, Is The Upside Already Priced In?

Simply Wall St.
·
Yesterday

Funds: What a Top Biotech Fund is Buying Now

Dow Jones
·
Yesterday

Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims

TIPRANKS
·
Aug 21

Sweden's Medivir Q2 Turnover Falls

Reuters
·
Aug 20

Telix Swings to H1 FY26 Net Profit of US$38 Million; Revenue Rises 22% to Us$477 Million

Reuters
·
Aug 20

Regeneron to Webcast Management Presentation at Wells Fargo Healthcare Conference

Reuters
·
Aug 20

Regeneron Announces Investor Conference Presentations

GlobeNewswire
·
Aug 20

Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition

MT Newswires Live
·
Aug 20

US FDA Approves Regeneron's Rare Bone Disorder Drug

Reuters
·
Aug 20

Regeneron Says FDA Approves Pasatru for Adults with Rare Bone Disorder FOP

Reuters
·
Aug 20

Regeneron Pharmaceuticals, - Pasatru Under Review by European Medicines Agency; Global Submissions Planned

THOMSON REUTERS
·
Aug 20

Regeneron Pharmaceuticals, - FDA Approves Pasatru (Garetosmab-Grts) for Adults with Fibrodysplasia Ossificans Progressiva

THOMSON REUTERS
·
Aug 20

Movement Alert|Regeneron Pharmaceuticals Rises 3.44% in Regular Trading, Investment Bank Sharply Raises Target Price Amid Biotech Sector Rally

Market Focus
·
Aug 19

What This Top Biotech Fund is Buying Now

Dow Jones
·
Aug 19

Regeneron Pharma Price Target Raised to $824.00/Share from $641.00 by Leerink Partners

Dow Jones
·
Aug 17

EyePoint Tumbles After Experimental Eye Drug Misses Main Goal in Late-Stage Study

Reuters
·
Aug 17

Leerink Partners Adjusts PT on Regeneron Pharmaceuticals to $824 From $641, Maintains Market Perform Rating

MT Newswires Live
·
Aug 17

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating

MT Newswires Live
·
Aug 14

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 14

Regeneron Director Huda Y. Zoghbi Disposes of USD 640,000 in Common Shares

Reuters
·
Aug 13